RBC Keeps Incyte (INCY) at 'Outperform'; ECHO-202 Abstract Shows Increase in ORR, but PFS Not Reached
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Dow up on UnitedHealth boost; higher bond yields, Mideast tensions cap gains
- Tesla stock tests 1-year lows as market cap drops below $500 billion
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- BofA profit drops as provisions rise, but beats estimates on investment banking surge
- Morgan Stanley (MS) earnings beat lifts stock
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab)
September 28, 2016 6:11 AM EDTIncytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy is well-tolerated and demonstrates durable clinical response in patients with treatment-naïve advanced melanoma
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) today announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1110PD) containing updated data from the Phase 1 portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incytes selective IDO1 enzyme inhibitor, in combination with Keytruda® (pembrolizumab), Mercks anti-PD-1 therapy. These data will be highlighted in a poster discussion on... More
